Sponsor: IPSEN Bioscience, Inc.
A randomized, phase 3 trial of irinotecan liposomal injection versus topotecan in small cell lung cancer patients that have previously progressed after being treated with first line platinum-based chemotherapy.
For more information please contact the clinical research department: 631-675-5075